Abstract
By the end of this chapter you should be able to:
-
Describe three product-based global public-private partnerships that concern medicines.
-
Describe three product-development-based global public-private partnerships that concern medicines.
-
Describe three systems/issues-based global public-private partnerships that concern medicines.
-
List the objectives of the Global Alliance for Vaccines and Immunisation (GAVI).
-
List the objectives of the Global Fund to fight AIDS, tuberculosis and malaria.
-
Describe the WHO pre-qualification project.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Further reading
Brugha, R., Starling, M. and Walt, G. (2002) “GAVI, the first steps: lessons for the Global Fund”, Lancet 359: 435–358.
Buse, K. and Walt, G. (2000) “Global Public-Private Partnerships: Part II-What are the health issues for global governance?”, Bulletin of the World Health Orga-nization 78 (5): 699–708. http://www.who.int/docstore/bulletin/pdf/2000/issue5/bu0241.pdf.
Correa, C. (2000) Intellectual Property Rights,the WTO and Developing Countries: The TRIPS Agreement and Policy Options. New York: Zed Books, Third Work Network.
Global Drug Facility (2004) An Initiative of the Global Partnership to Stop TB. http://www.stoptb.org/GDF/defaultasp.
Global Fund (2004) http://www.theglobalfund.org/en/.
Implementation of the Doha Declaration on the TRIPS Agreement and Public Health: Technical Assistance — How to Get it Right (2002) Conference Report. 28th March 2002, International Conference Centre of Geneva (CICG): Medecins sans Frontieres (MSF), Health Action International (HAI), Consumer Project on Technology (CPT), Oxfam International.
Love, J. (2003) From TRIPS to RIPS: A Better Trade Framework to Support Innovation in Medical Technologies. Presented at the Workshop on Economic issues related to access to HIV/AIDS care in developing countries, Université de la Méditerranée, Marseille, France, May 27th, 2003. http://www.cptech.org/slides/trips2rips.doc.
Quick, J. (2003) “Essential medicines twenty-five years on: closing the access gap”, Health Policy and Planning 18 (1): 1–3.
Quick, J. and Hogerzeil, H. (2003) “Ten best readings in… essential medicines”, Health Policy and Planning 18 (1): 119–121.
US Bullying on Drug Patents: One Year after Doha (2002) Oxfam Briefing Paper No. 33. http://www.oxfam.ca/campaigns/downloads/TRIPSbriefUSbullying2.pdf.
Velasquez, G. and Boulet, P. (1999) “Essential drugs in the new international economic environment”, Bulletin of the World Health Organization 77 (3): 288–292.
WHO Pre-Qualification Scheme (2004) Geneva: World Health Organization. Pre-qualification project website. http://mednet3.who.int/prequal/.
Widdus, R. (2001) “Public-private partnerships for health: their main targets, their diversity, and their future directions”, Bulletin of the World Health Organization 79 (8): 713–720.
Rights and permissions
Copyright information
© 2004 Springer Basel AG
About this chapter
Cite this chapter
Anderson, S., Summers, R. (2004). Policy Initiatives and their Implications. In: Managing Pharmaceuticals in International Health. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7913-2_14
Download citation
DOI: https://doi.org/10.1007/978-3-0348-7913-2_14
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-7643-6601-8
Online ISBN: 978-3-0348-7913-2
eBook Packages: Springer Book Archive